Welcome to the Third 2017 Issue of The CLL Tribune.ClicK here: http://cllsociety.org/quarter-3-2017-volume-3-issue-3/ to read the Front Page.
We've Come a Long Way-Together.We must be doing something that is needed as over 3000 visited the website the first day the newsletter was posted. I am proud and humbled by that response.It's hard to believe that two years have passed since the first issue of the CLL Tribune. Time goes by so quickly. And, even more remarkable, so much has happened in the CLL community in the last two years. While effective new therapies are in use, and promising ones are on the horizon, statistics alone estimate that more than 40,000 people were diagnosed with CLL during this time. But CLLsociety.org and the CLL Tribune were both there to help the newly diagnosed, as well as the CLL veteran. More than 2,500 people subscribe to the quarterly newsletter and the number climbs monthly.The CLL Tribune and the CLL Society's website, however, would not be possible with you-the CLL patient or caregiver who walks your own special journey with this still largely incurable disease. More than 45 of you have written newsletter articles to share your knowledge and experience. We would love to have more patient or caregiver authors - reach out to us here. Twenty-seven have stepped up to lead CLL Society patient support groups in their cities with more planned to start in the near future. More than 1,000 have participated in our patient and caregiver surveys. Plus, your tax deductible contributions to the CLL Society have helped keep our mission alive. Find out more about all the things we have accomplished together http://cllsociety.org/donate-to-cll-society/
Thank you all. Stay strong. We are all in this together.If you want a personal response, or just want to stay in touch, please email me at [email protected]. I have no other way of contacting. Thanks. Stay strong. After all, we are all in this together. And please visit our website: http://cllsociety.org for the latest news and information.
Community Magazine
Author's Latest Articles
-
A Matching-Adjusted Indirect Comparison of Acalabrutinib Vs. Zanubrutinib in Relapsed Or Refractory CLL
-
My Personal Decision to Restart My CLL (chronic Lymphocytic Leukemia) Treatment
-
ASH 2022: Adverse Events from BTK Inhibitors in Clinical Trials
-
Dr. Stephan Stilgenbauer on the Evolution of CLL to Richter’s Syndrome from ASH 2022